Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027

Cartesian Therapeutics, Inc.

Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.
Term loans bear interest at 8.95% or prime+2.20% (whichever greater); matures June 1, 2030 with monthly amortization from July 2029.
CMO Milos Miljkovic resigns effective May 31, 2026; will receive severance including six months' salary and COBRA coverage.
Phase 3 AURORA topline data for Descartes-08 in myasthenia gravis expected in Q1 2027; BLA filing planned for mid-2027.
Cash runway extended into 2028; Phase 2 TRITON and Phase 1/2 HELIOS data expected in H1 2027.

item 1.01 item 2.03 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Milos Miljkovic

Chief Medical Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2026-05-31
Filed: May 26, 2026, 7:08 AM ET

On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Milos Miljkovic resigned as Chief Medical Officer at Cartesian Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Cartesian Therapeutics, Inc. entered into Loan and Security Agreement with certain financial institutions party thereto as lenders, K2 HealthVentures LLC, as administrative agent and Ankura Trust Company, LLC, as collateral trustee valued at up to $150.0 million (effective 2026-05-22).

Action: entry
Agreement: credit facility
Counterparty: certain financial institutions party thereto as lenders, K2 HealthVentures LLC, as administrative agent and Ankura Trust Company, LLC, as collateral trustee
Value: up to $150.0 million
Effective: 2026-05-22

Exact text from the filing

On May 22, 2026, Cartesian Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, Cartesian Bio, LLC, as borrowers (“Borrowers”), entered into a Loan and Security Agreement (the “Loan Agreement”) with certain financial institutions party thereto as lenders (the “Lenders”), K2 HealthVentures LLC, as administrative agent (in such capacity, the “Administrative Agent”) and Ankura Trust Company, LLC, as collateral trustee (in such capacity, the “Collateral Trustee”). The Loan Agreement provides for senior secured term loans in an aggregate principal amount of up to $150.0 million

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-26-000087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.